Read by QxMD icon Read

Journal of Neuro-oncology

Amaury De Barros, Justine Attal, Margaux Roques, Julien Nicolau, Jean-Christophe Sol, Elizabeth Cohen-Jonathan-Moyal, Franck-Emmanuel Roux
PURPOSE: Systematic pre-radiotherapy MRI in patients with newly resected glioblastoma (OMS 2016) sometimes reveals tumor growth in the period between surgery and radiotherapy. We evaluated the relation between early tumor growth and overall survival (OS) with the aim of finding predictors of regrowth. METHODS: Seventy-five patients from 25 to 84 years old (Median age 62 years) with preoperative, immediate postoperative, and preradiotherapy MRI were included. Volumetric measurements were made on each of the three MRI scans and clinical and molecular parameters were collected for each case...
February 19, 2019: Journal of Neuro-oncology
M Kerkhof, J A F Koekkoek, M J Vos, M J van den Bent, W Taal, T J Postma, J E C Bromberg, M C M Kouwenhoven, L Dirven, J C Reijneveld, M J B Taphoorn
BACKGROUND: When glioma patients experience long-term seizure freedom the question arises whether antiepileptic drugs (AEDs) should be continued. As no prospective studies exist on seizure recurrence in glioma patients after AED withdrawal, we evaluated the decision-making process to withdraw AEDs in glioma patients, and seizure outcome after withdrawal. METHODS: Patients with a histologically confirmed low grade or anaplastic glioma were included. Eligible patients were seizure free ≥ 1 year from the date of last antitumor treatment, or ≥ 2 years since the last seizure when seizures occurred after the end of the last antitumor treatment...
February 18, 2019: Journal of Neuro-oncology
Dana L Casey, Kenneth L Pitter, Brandon S Imber, Andrew Lin, Timothy A Chan, Kathryn Beal, Yoshiya Yamada, Darren R Feldman, T Jonathan Yang
PURPOSE: The presence of brain metastases (BM) in patients with non-seminomatous germ cell tumor (NSGCT) is associated with poor prognosis. While radiation therapy (RT) is an important treatment for patients with NSGCT BM, there is a paucity of data on the optimal regimen. We sought to investigate the impact of RT on clinical outcomes in patients with NSGCT BM. METHODS: Patients with NSGCT BM who received RT at our institution from 2002 to 2017 were included. Sixty-three consecutive patients were identified...
February 15, 2019: Journal of Neuro-oncology
Jiayi Huang, Rekha Chaudhary, Adam L Cohen, Karen Fink, Samuel Goldlust, John Boockvar, Prakash Chinnaiyan, Leping Wan, Stephen Marcus, Jian L Campian
PURPOSE: Preclinical studies have suggested promising activity for the combination of disulfiram and copper (DSF/Cu) against glioblastoma (GBM) including re-sensitization to temozolomide (TMZ). A previous phase I study demonstrated the safety of combining DSF/Cu with adjuvant TMZ for newly diagnosed GBM. This phase II study aimed to estimate the potential effectiveness of DSF/Cu to re-sensitize recurrent GBM to TMZ. METHODS: This open-label, single-arm phase II study treated recurrent TMZ-resistant GBM patients with standard monthly TMZ plus concurrent daily DSF 80 mg PO TID and Cu 1...
February 15, 2019: Journal of Neuro-oncology
Compes Paloma, Tabouret Emeline, Etcheverry Amandine, Colin Carole, Appay Romain, Cordier Nicolas, Mosser Jean, Chinot Olivier, Delingette Hervé, Girard Nadine, Dufour Henry, Metellus Philippe, Figarella-Branger Dominique
INTRODUCTION: The phenotypic heterogeneity of diffuse gliomas is still inconsistently explained by known molecular abnormalities. Here, we report the molecular and radiological features of diffuse grade WHO II and III gliomas involving the insula and its potential impact on prognosis. METHODS: Clinical, pathological, molecular and neuro-radiological features of 43 consecutive patients who underwent a surgical resection between 2006 and 2013 for a grade II and III gliomas involving the insula was retrospectively analyzed...
February 11, 2019: Journal of Neuro-oncology
Brittany Liebenow, Abigail Tatter, William A Dezarn, Scott Isom, Michael D Chan, Stephen B Tatter
PURPOSE: This is the first single-institution study of its size to characterize the treatment impact and to address the question of whether hemangioblastoma treatment with Gamma Knife Stereotactic Radiosurgery (GKRS) in both sporadic and VHL patients changes the characteristic saltatory hemangioblastoma growth pattern. METHODS: The authors reviewed a single-institution tumor registry to identify patients who had received GKRS for hemangioblastomas between January 1st, 1999, and December 31st, 2017...
February 7, 2019: Journal of Neuro-oncology
Antonio Silvani, Irene De Simone, Vittorio Fregoni, Elena Biagioli, Enrico Marchioni, Manuela Caroli, Andrea Salmaggi, Andrea Pace, Valter Torri, Paola Gaviani, Erica Quaquarini, Giorgia Simonetti, Eliana Rulli, Maurizio D'Incalci
BACKGROUND AND PURPOSE: Glioblastoma (GBM) is the most aggressive and frequent subtype of all malignant gliomas. At the time of recurrence, therapeutic options are lacking. Ortataxel, a second-generation taxane was reported to be effective in pre-clinical and phase I clinical studies. The aim of this study was to evaluate a potential therapeutic activity of ortataxel in patients with GBM recurring after surgery and first line treatment. METHODS: In this phase II study, according to a two stage design, adult patients with histologically confirmed GBM in recurrence after surgery or biopsy, standard radiotherapy and chemotherapy with temozolomide were considered eligible...
February 6, 2019: Journal of Neuro-oncology
Laura Kallay, Havva Keskin, Alexandra Ross, Manali Rupji, Olivia A Moody, Xin Wang, Guanguan Li, Taukir Ahmed, Farjana Rashid, Michael Rajesh Stephen, Kirsten A Cottrill, T Austin Nuckols, Maxwell Xu, Deborah E Martinson, Frank Tranghese, Yanxin Pei, James M Cook, Jeanne Kowalski, Michael D Taylor, Andrew Jenkins, Daniel A Pomeranz Krummel, Soma Sengupta
PURPOSE: Pediatric brain cancer medulloblastoma (MB) standard-of-care results in numerous comorbidities. MB is comprised of distinct molecular subgroups. Group 3 molecular subgroup patients have the highest relapse rates and after standard-of-care have a 20% survival. Group 3 tumors have high expression of GABRA5, which codes for the α5 subunit of the γ-aminobutyric acid type A receptor (GABAA R). We are advancing a therapeutic approach for group 3 based on GABAA R modulation using benzodiazepine-derivatives...
February 6, 2019: Journal of Neuro-oncology
Rachel H Brigell, Daniel N Cagney, Allison M Martin, Luke A Besse, Paul J Catalano, Eudocia Q Lee, Patrick Y Wen, Paul D Brown, John G Phillips, Itai M Pashtan, Shyam K Tanguturi, Daphne A Haas-Kogan, Brian M Alexander, Ayal A Aizer
PURPOSE: Brain metastases can be radiographically cystic or solid. Cystic metastases are associated with a greater intracranial disease burden and poorer oncologic outcomes, but the impact of cystic versus solid appearance on local control after radiation remains unknown. We investigated whether cystic versus solid nature is predictive of local control after management with stereotactic or whole brain radiation (WBRT) and whether the radiation modality utilized is an effect modifier. METHODS: We identified 859 patients with 2211 newly-diagnosed brain metastases managed with upfront stereotactic radiation or WBRT without preceding resection/aspiration at Brigham and Women's Hospital/Dana-Farber Cancer Institute between 2000 and 2015...
February 4, 2019: Journal of Neuro-oncology
Kiyong Na, Hyun-Soo Kim, Hyo Sup Shim, Jong Hee Chang, Seok-Gu Kang, Se Hoon Kim
PURPOSE: The TruSight Tumor 170 (TST-170) panel consists of a DNA workflow for the identification of single-nucleotide variants, small insertions and deletions, and copy number variation, as well as a panel of 55 genes for a RNA workflow for the identification of splice variants and gene fusions. To date, the application of TST-170 in diffuse gliomas (DGs) has not been described. METHODS: We analyzed 135 samples of DG, which were diagnosed by WHO criteria based on histological features and conventional molecular tests including immunostaining, 1p/19q FISH, and analysis of MGMT methylation and TERT promoter mutation...
February 1, 2019: Journal of Neuro-oncology
Meijing Wu, Jason Miska, Ting Xiao, Peng Zhang, J Robert Kane, Irina V Balyasnikova, James P Chandler, Craig M Horbinski, Maciej S Lesniak
PURPOSE: To study whether the clinical outcome and molecular biology of gliomas in African-American patients fundamentally differ from those occurring in Whites. METHODS: The clinical information and molecular profiles (including gene expression array, non-silent somatic mutation, DNA methylation and protein expression) were downloaded from The Cancer genome atlas (TCGA). Electronic medical records were abstracted from Northwestern Medicine Enterprise Data Warehouse (NMEDW) for analysis as well...
January 31, 2019: Journal of Neuro-oncology
Che Jiang, Jiajia Wang
PURPOSE: The primary objective of this study was to investigate the incidence of PTSD at 3 months postoperatively in patients who were newly diagnosed with LGGs, and its association with 5-year survival. Moreover, QoL and other psychiatric disorders like depression and anxiety were also evaluated. METHODS: From February 2011 to April 2013, patients who underwent low-grade glioma surgery at our hospital and come back for reexamination at 3-month follow-up were considered for this study...
January 31, 2019: Journal of Neuro-oncology
Junichi Sakata, Takashi Sasayama, Kazuhiro Tanaka, Hiroaki Nagashima, Mitsutoshi Nakada, Hirotomo Tanaka, Naoya Hashimoto, Naoki Kagawa, Manabu Kinoshita, Satoshi Nakamizo, Masahiro Maeyama, Masamitsu Nishihara, Kohkichi Hosoda, Eiji Kohmura
BACKGROUND: MicroRNAs (miRs) regulate many biological processes, such as invasion, angiogenesis, and metastasis. Glioblastoma (GBM) patients with metastasis/metastatic dissemination have a very poor prognosis; therefore, inhibiting metastasis/metastatic dissemination has become an important therapeutic strategy for GBM treatment. METHODS: Using 76 GBM tissues, we examined the expression levels of 23 GBM-related miRs and compared the miRs' expression levels between GBMs with metastasis/metastatic dissemination and GBMs without metastasis/metastatic dissemination...
January 30, 2019: Journal of Neuro-oncology
Ahmed Musah-Eroje, Sue Watson
PURPOSE: Glioblastoma (GBM) is the most common invasive malignant brain tumour in adults. It is traditionally investigated in vitro by culturing cells as a monolayer (2D culture) or as neurospheres (clusters enriched in cancer stem cells) but neither system accurately reflects the complexity of the three-dimensional (3D) chemoresistant microenvironment of GBM. MATERIALS AND METHODS: Using three GBM cell-lines (U87, U251, and SNB19), the effect of culturing cells in a Cultrex-based basement membrane extract (BME) [3D Tumour Growth Assay (TGA)] on morphology, gene expression, metabolism, and temozolomide chemoresistance was investigated...
January 29, 2019: Journal of Neuro-oncology
Xiu-Jian Ma, Da Li, Liang Wang, Shu-Yu Hao, Li-Wei Zhang, Jun-Ting Zhang, Zhen Wu
The article Clinical features, radiological profiles, and surgical outcomes of primary intracranial solitary plasmacytomas: a report of 17 cases and a pooled analysis of individual patient data, written by Xiu-Jian Ma, Da Li, Liang Wang, Shu-Yu Hao, Li-Wei Zhang, Jun-Ting Zhang, Zhen Wu, was originally published electronically on the publisher's internet portal (currently SpringerLink) on 7 January 2019 with open access. With the authors' decision to step back from Open Choice, the copyright of the article changed on 25 January 2019 to © Springer Science + Business Media, LLC, part of Springer Nature 2019 and the article is forthwith distributed under the terms of copyright...
January 25, 2019: Journal of Neuro-oncology
Koos E Hovinga, Heather J McCrea, Cameron Brennan, Jason Huse, Junting Zheng, Yoshua Esquenazi, Katherine S Panageas, Viviane Tabar
PURPOSE: The highly vascular malignant brain tumor glioblastoma (GBM) appears to be an ideal target for anti-angiogenic therapy; however, clinical trials to date suggest the VEGF antibody bevacizumab affects only progression-free survival. Here we analyze a group of patients with GBM who received bevacizumab treatment at recurrence and are stratified according to tumor molecular and genomic profile (TCGA classification), with the goal of identifying molecular predictors of the response to bevacizumab...
January 24, 2019: Journal of Neuro-oncology
Kyle R Noll, Catherine M Sullaway, Jeffrey S Wefel
INTRODUCTION: Depression and neurocognitive function, particularly executive functioning (EF), have been associated with overall survival (OS) in patients with glioblastoma (GBM). However, the combined effect of depressive symptoms and impaired EF upon OS has not been reported. METHODS: Patients with GBM (N = 102) completed neuropsychological assessment postoperatively, including the Beck Depression Inventory-Second Edition (BDI-II) and the Trail Making Test Part B (TMTB)...
January 24, 2019: Journal of Neuro-oncology
Constantinos G Hadjipanayis, Walter Stummer, Jason P Sheehan
No abstract text is available yet for this article.
January 22, 2019: Journal of Neuro-oncology
Jacob J Mandel, Michael Youssef, Jooyeon Nam, Akash J Patel, Ali Jalali, Ethan B Ludmir, Diane Liu, Jimin Wu, Georgina Armstrong, Jason Huse, Melissa Bondy, John F de Groot
BACKGROUND: Examine the potential effects of health disparities in survival of glioblastoma (GB) patients. METHODS: We conducted a retrospective chart review of newly diagnosed GB patients from 2000 to 2015 at a free standing dedicated cancer center (MD Anderson Cancer Center-MDACC) and a safety net county hospital (Ben Taub General Hospital-BT) located in Houston, Texas. We obtained demographics, insurance status, extent of resection, treatments, and other known prognostic variables (Karnofsky Score-KPS) to evaluate their role on overall GB survival (OS)...
January 22, 2019: Journal of Neuro-oncology
Zjiwar H A Sadik, Laurens V Beerepoot, Patrick E J Hanssens
OBJECTIVE: Gynecological brain metastases (BM) are rare and usually develop as part of widespread disseminated disease. Despite treatment, the majority of these patients do not survive > 1 year due to advanced extracranial disease. The use of Gamma Knife Radiosurgery (GKRS) for gynecological BM is not well known. The goal of this study is to evaluate the efficacy of GKRS for gynecological BM. METHODS: We performed a retrospective study of patients with gynecological BM who underwent GKRS between 2002 and 2015...
January 21, 2019: Journal of Neuro-oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"